title: Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed.
abstract: OBJECTIVE
  To report the 12-month outcomes of the dexamethasone intravitreal implant in retinal vein occlusion (RVO), using an as-needed repeat injection protocol.
  
  
  METHODS
  Retrospective consecutive case series of 51 eyes of 49 patients with macular oedema as a result of RVO that received an intravitreal dexamethasone implant and were followed up for at least 12 months.
  
  
  RESULTS
  70% of patients responded to dexamethasone implant injection with an improvement in visual acuity (VA) and macular oedema within 3 months of injection, but only 30% of eyes gained ≥15 letters. The mean change in VA letter score at 12 months compared with baseline for branch RVO (BRVO) and central RVO (CRVO) was 5.7±2.3 and 11.5±11.0 EDTRS letters, respectively. 56% of patients relapsed, with the median time to relapse being 17 weeks for patients with branch RVO and 18 weeks for patients with CRVO. Repeat injections achieved similar VA gains, but the duration of effect of repeat dexamethasone implants was much shorter at 10 weeks. 14 eyes (27%) developed a significant rise in intraocular pressure, and three of these required treatment with oral acetazolamide. Four eyes with CRVO developed neovascular glaucoma during the study.
  
  
  CONCLUSIONS
  The intravitreal dexamethasone implant does not last the 6 months implied by the retreatment protocol in the GENEVA trial, and improved results can be achieved with an as-needed retreatment protocol, particularly in CRVO. However, visual outcomes remain similar to those previously seen with triamcinolone in the SCORE study and neovascular complications remain a feature of CRVO.
authors.affiliation: Department of Ophthalmology, Royal Surrey County Hospital NHS Foundation Trust, Guildford, Surrey, UK.
authors.forename: Lavnish
authors.initials: L
authors.lastname: Joshi
authors.forename: Satish
authors.initials: S
authors.lastname: Yaganti
authors.forename: Maria
authors.initials: M
authors.lastname: Gemenetzi
authors.forename: Sue
authors.initials: S
authors.lastname: Lightman
authors.forename: Dan
authors.initials: D
authors.lastname: Lindfield
authors.forename: Vasilis
authors.initials: V
authors.lastname: Liolios
authors.forename: Victor
authors.initials: V
authors.lastname: Menezo
authors.forename: Emily
authors.initials: E
authors.lastname: Shao
authors.forename: Simon R J
authors.initials: SR
authors.lastname: Taylor
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects; D004343:Drug Implants; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D021621:Imaging, Three-Dimensional; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D019233:Retreatment; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone
keywords: Retina; Treatment Medical